Memorandum of Understanding Between the Food and Drug Administration, National Center for Toxicological Research, and the Air Force Research Laboratory, 711 Human Performance Wing, Human Effectiveness Directorate, Biosciences and Protection Division, for Toxicity of Nanomaterials, 43706-43713 [E9-20634]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 74, Number 165 (Thursday, August 27, 2009)]
[Notices]
[Pages 43706-43713]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20634]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0667]
[FDA 09-209-RH-03MOU]


Memorandum of Understanding Between the Food and Drug 
Administration, National Center for Toxicological Research, and the Air 
Force Research Laboratory, 711 Human Performance Wing, Human 
Effectiveness Directorate, Biosciences and Protection Division, for 
Toxicity of Nanomaterials

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is providing notice of 
a memorandum of understanding (MOU) between FDA and the Air Force 
Research Laboratory. This Memorandum of Understanding (MOU) between the 
Food and Drug Administration, National Center for Toxicological 
Research (NCTR), and the Air Force Research Laboratory, 711 Human 
Performance Wing, Human Effectiveness Directorate, Biosciences and 
Protection Division, Applied Biotechnology Branch (711 HPW/RHPB) 
(hereinafter referred to as ``the Parties''), sets forth the agreement 
of the Parties to facilitate information sharing in the area of 
toxicogenomic and computational toxicology research. Through the 
exchange of information, the Parties intend to coordinate research 
efforts so as to identify and expedite research and development of new 
tools and technologies that can be implemented that promote new 
understanding of the mechanisms of biological responses to 
environmental stressors, including toxic injury, and to identify 
biomarkers of exposure and disease that can be used to improve and 
protect human health.

DATES: The agreement became effective July 28, 2009.

FOR FURTHER INFORMATION CONTACT:
Points of Contact: The following are Responsible Officers in NCTR and 
711 HPW/RHP:
    (1) For NCTR: William Slikker, Jr., Director, National Center for 
Toxicological Research, Food and Drug Administration, 3900 NCTR Rd., 
Jefferson, AR 72079-9501, phone: 870-543-7950, fax: 870-543-7576, e-
mail: william.slikker@fda.hhs.gov.
    (2) For 711 HPW/RHPB: John J. Schlager, Chief, Applied 
Biotechnology Branch, 2729 R St., Wright-Patterson AFB, OH 45433-5707, 
phone: 937-904-9570, fax: 937-255-1474, e-mail: 
john.schlager@wpafb.af.mil.
Points of Contact: The following are Principal Investigators in NCTR 
and 711 HPW/RHP:
    (1) For NCTR: Syed F. Ali, Senior Biomedical Research Scientist, 
National Center for Toxicological Research, Food and Drug 
Administration, 3900 NCTR Rd., Jefferson, AR 72079-9501, phone: 870-
543-7123, fax: 870-543-7745, e-mail: syed.ali@fda.hhs.gov.
    (2) For 711 HPW/RHPB: Saber M. Hussain, Scientist, Group Lead, 
Biological Interaction of Nanomaterials, 2729 R St., Wright-Patterson 
AFB, OH 45433-5707, phone: 937-904-9517, fax: 937-904-9610, e-mail: 
saber.hussain@wpafb.af.mil.
Points of Contact: The following are points of contact for Agreement 
Administration in NCTR and 711 HPW:
    (1) For NCTR: Thomas J. Flammang, Deputy Director, Office of 
Research, National Center for Toxicological Research, Food and Drug 
Administration, 3900 NCTR Rd., Jefferson, AR 72079-9501, phone: 870-
543-7291, fax: 870-543-7576, e-mail: thomas.flammang@fda.hhs.gov.
    (2) For 711 HPW/XPO: James D. Kearns, Technology Transfer Manager, 
2610 Seventh St., Wright-Patterson AFB, OH 45433-7901, phone: 937-255-
3765, fax: 937-255-7215, e-mail: jim.kearns@wpafb.af.mil.

SUPPLEMENTARY INFORMATION:  In accordance with 21 CFR 20.108(c), which 
states that all written agreements and MOUs between FDA and others 
shall be published in the Federal Register, the agency is publishing 
notice of this MOU.

    Dated: August 18, 2009.
David Horowitz,
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S

[[Page 43707]]

[GRAPHIC] [TIFF OMITTED] TN27AU09.192


[[Page 43708]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.193


[[Page 43709]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.194


[[Page 43710]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.195


[[Page 43711]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.196


[[Page 43712]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.197


[[Page 43713]]


[GRAPHIC] [TIFF OMITTED] TN27AU09.198

[FR Doc. E9-20634 Filed 8-26-09; 8:45 am]
BILLING CODE 4160-01-C